Overview:
Prospects for Commercialization of Human Monoclonal Antibodies is a
forthcoming addition to the Cambridge Healthtech Institute (CHI) Life Science
Report library. Monoclonal antibodies hold great promise both as tools for
drug discovery research and as therapeutics themselves. Leading nontherapeutic
applications include the use of these antibodies in target characterization and
validation, in diagnostics, and on protein arrays?one of the fastest-growing
areas in protein analysis. Therapeutic applications include targeted approaches
for treating cancer and other major diseases. Increasingly, small biotech and
genomic companies with a wealth of targets and a desire to reap the benefits of
developing their own drugs are partnering with major antibody developers such as
Medarex and Abgenix, as well as a host of smaller companies that can convert
those targets into potential antibody drugs. This strategy?which provides a
relatively low cost, low risk mode of entry into the pharmaceutical business?is
perhaps the largest factor driving the therapeutic antibody field.
This report, based on half a dozen interviews with leading experts in the
field, examines business and technological trends fueling the use of monoclonal
antibodies in drug discovery and development, and discusses how these trends
will influence the outlook for the field. A detailed analysis of
antibody-related dealmaking based on findings from CHI' s Drug Discovery and
Development Deals Database is also included.
View Cart
